

RNS Number : 1497T
EKF Diagnostics Holdings PLC
01 October 2014

**EKF Diagnostics Holdings plc
("EKF", the "Company")**

Director / PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, was informed on 1 October 2014 that David Evans, Executive Chairman, purchased shares in the Company on 1 October 2014.

David purchased 100,000 ordinary shares of 1 pence each in EKF at a purchase price of 23 pence per share. David's total shareholding following this purchase is 1,805,753 ordinary shares, which represents 0.43% of the Company's issued share capital.

Enquiries:

EKF Diagnostics Holdings plc
Julian Baines, CEO

Tel: 029 2071 0570
Mob: 07788 420 859

Canaccord Genuity Limited
Nominated Adviser/Corporate Broking
Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor

Tel: 020 7523 8350

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or ekf@walbrookpr.com
Mob: 07980 541 893
Mob: 07584 391 303

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSBGBDGUXGBGSB admin Director/PDMR Shareholding 22096374 A Wed, 10/01/2014 - 11:36
Directors' Dealings EKF